Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carfilzomib
Drug ID BADD_D00367
Description Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]
Indications and Usage Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.[L39392]
Marketing Status approved; investigational
ATC Code L01XG02
DrugBank ID DB08889
KEGG ID D08880
MeSH ID C524865
PubChem ID 11556711
TTD Drug ID D00UVA
NDC Product Code 76055-0035; 76075-103; 76075-101; 63552-009; 67262-0010; 42385-731; 76075-102; 63552-035; 54893-0037; 52076-6251; 55111-985; 11722-059
UNII 72X6E3J5AR
Synonyms carfilzomib | PR-171 | PR171 | Kyprolis
Chemical Information
Molecular Formula C40H57N5O7
CAS Registry Number 868540-17-4
SMILES CC(C)CC(C(=O)C1(CO1)C)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(C)C)NC(=O)C(CCC3=CC=CC=C3) NC(=O)CN4CCOCC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual field defect17.17.01.001; 06.02.07.0030.000246%Not Available
Vomiting07.01.07.003--
Vomiting projectile07.01.07.0120.000381%Not Available
Wheezing22.03.01.0090.000907%
Mental status changes19.07.01.0010.000750%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.0300.001780%Not Available
Musculoskeletal disorder15.03.05.0250.000492%Not Available
Cardiotoxicity02.11.01.009; 12.03.01.0070.001287%Not Available
Infusion site erythema12.07.05.009; 08.02.05.008; 23.03.06.0160.002697%Not Available
Poor venous access24.03.02.0170.000627%Not Available
Hypoacusis04.02.01.0060.001768%
Peripheral swelling08.01.03.053; 02.05.04.0150.006190%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.0160.000168%Not Available
General physical health deterioration08.01.03.0180.001824%Not Available
Left ventricular dysfunction02.04.02.0110.000280%
Muscle tightness15.05.03.0070.000437%Not Available
Cardiac death08.04.01.007; 02.03.04.0150.000112%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000302%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000907%
Lower gastrointestinal haemorrhage24.07.02.030; 07.12.03.0110.000112%
Systemic inflammatory response syndrome10.02.01.008; 08.01.05.005; 24.06.03.0080.000168%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000336%Not Available
Infusion related reaction12.02.05.009; 10.01.01.017; 08.01.03.002--
Cytokine release syndrome10.02.01.0100.000224%
Respiratory tract congestion22.02.07.0030.000246%Not Available
Diastolic dysfunction02.04.02.0220.000470%Not Available
Musculoskeletal discomfort15.03.04.0010.000571%Not Available
Organ failure08.01.03.0410.000224%Not Available
Secretion discharge08.01.03.0190.000112%Not Available
Infusion site induration12.07.05.010; 08.02.05.0090.000381%Not Available
The 9th Page    First    Pre   9 10 11 12    Next   Last    Total 12 Pages